Abstract
INTRODUCTION
In this study, the effects of changes in coagulation tests on survival and distant organ metastasis in lung cancer patients were investigated.
METHODS
We retrospectively evaluated the data of patients who were diagnosed with primary lung cancer by our radiation oncology clinic. The relationship between age, sex, histopathological diagnosis, metastasis status and coagulation test values and lifespan were analyzed.
RESULTS
A total of 342 patients were included in the study. 18,4% of the patients had small cell lung cancer (SCLC), and 81,6% had non-small cell lung cancer (NSCLC). Adenocarcinoma (45.0%) was the most common histopathological subtype in patients with NSCLC. When distant organ metastasis rates were handled for all patients, while there weren’t distant organ metastasis in 44.4% of patients, distant organ metastasis was found out in 55.6% of the patients. 65.1% of patients with SCLC and 53.4% of patients with SCLC were in advanced stages with distant organ metastasis. 18.4% of the patients had brain metastasis, and 81.6% had no brain metastasis. There was no statistically significant effect of APTT, PT, INR, % PT which are among the coagulation tests, and fibrinogen values on brain metastasis status and survival (p> 0.05). However, in patients with brain metastases, increase in the ratio close to statistical significance the INR and% PT values was found (p = 0.068, p = 0.059, respectively) when compared to the non-men.
DISCUSSION AND CONCLUSION
In the case of lung cancer, an increase in the frequency of brain metastasis may be associated with the hypothesis that prolongation of the coagulation test and deterioration of the blood-brain barrier, but there is a need for extensive studies with more patients.